Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 36.48
OHRP's Cash-to-Debt is ranked higher than
50% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OHRP: 36.48 )
Ranked among companies with meaningful Cash-to-Debt only.
OHRP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 158.85 Max: No Debt
Current: 36.48
Piotroski F-Score: 2
Altman Z-Score: -5.96
WACC vs ROIC
7.27%
-243.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -108.20
OHRP's ROE % is ranked lower than
80% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. OHRP: -108.20 )
Ranked among companies with meaningful ROE % only.
OHRP' s ROE % Range Over the Past 10 Years
Min: -267.49  Med: -66.72 Max: 427.71
Current: -108.2
-267.49
427.71
ROA % -91.64
OHRP's ROA % is ranked lower than
83% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. OHRP: -91.64 )
Ranked among companies with meaningful ROA % only.
OHRP' s ROA % Range Over the Past 10 Years
Min: -1157.76  Med: -63.5 Max: 37.38
Current: -91.64
-1157.76
37.38
ROC (Joel Greenblatt) % -14507.98
OHRP's ROC (Joel Greenblatt) % is ranked lower than
89% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. OHRP: -14507.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OHRP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23716.28  Med: -10980.36 Max: 4300
Current: -14507.98
-23716.28
4300
3-Year EBITDA Growth Rate 36.00
OHRP's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. OHRP: 36.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OHRP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.4 Max: 82.7
Current: 36
0
82.7
3-Year EPS without NRI Growth Rate 39.80
OHRP's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OHRP: 39.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OHRP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -1  Med: 22.2 Max: 75.4
Current: 39.8
-1
75.4
GuruFocus has detected 2 Warning Signs with Ohr Pharmaceutical Inc $OHRP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OHRP's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CHMA, OTCPK:NWBO, OTCPK:CVALF, OTCPK:COTXF, NAS:DMTX, NAS:TCON, NAS:NVLS, NAS:BVXV, NAS:TPIV, AMEX:IBIO, NAS:CYTX, NAS:TRIL, NAS:EBIO, AMEX:BPMX, OTCPK:GBLX, NAS:ICCC, OTCPK:MDBIF, OTCPK:THCBF, OTCPK:MRNA, NAS:CBLI » details
Traded in other countries:O7P1.Germany,
Headquarter Location:USA
Ohr Pharmaceutical Inc is a pharmaceutical company engaged in development of novel therapeutics and delivery technologies for the treatment of ocular disease.

Ohr Pharmaceutical Inc is a Delaware corporation organized on August 4, 2009, as successor to, BBM Holdings, Inc., pursuant to a reincorporation merger. The Company is a pharmaceutical company engaged in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The Company has submitted a Special Protocol Assessment (SPA) request to the FDA, as part of its ongoing interactions with the FDA on the detailed design of the Phase III clinical development program of OHR-102. The drug acts against the development of aberrant neovascularization by inhibiting multiple protein growth factors of angiogenesis, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor growth factor (bFGF). The Company is subject to regulation by federal, state and local government authorities, including the FDA.

Top Ranked Articles about Ohr Pharmaceutical Inc

Ohr Pharmaceutical to Present at the 2017 Marcum Microcap Conference
Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings
Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors
Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11
Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the Cowen & Company 37th Annual Health Care Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston Massachusetts.
Ohr Pharmaceutical Presentation Details    
Date:Monday, March 6Time: 4:40pm Eastern TimeLocation:                Regis Ballroom, 3rd Floor  About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as Squalamine or OHR-102), is currently being studied as an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact:
Ohr Pharmaceutical Inc.
Investor Relations
888-388-2327
[email protected]

LifeSci Advisors, LLC
Michael Wood
646-597-6983
[email protected]


Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.22
OHRP's PB Ratio is ranked higher than
89% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. OHRP: 1.22 )
Ranked among companies with meaningful PB Ratio only.
OHRP' s PB Ratio Range Over the Past 10 Years
Min: 1.2  Med: 13.89 Max: 17.86
Current: 1.22
1.2
17.86
Current Ratio 1.43
OHRP's Current Ratio is ranked lower than
82% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OHRP: 1.43 )
Ranked among companies with meaningful Current Ratio only.
OHRP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.52 Max: 24.65
Current: 1.43
0.04
24.65
Quick Ratio 1.43
OHRP's Quick Ratio is ranked lower than
78% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OHRP: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
OHRP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.52 Max: 24.65
Current: 1.43
0.04
24.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.60
OHRP's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. OHRP: -17.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OHRP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -129.9  Med: -23.2 Max: 10.2
Current: -17.6
-129.9
10.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.00
OHRP's Price-to-Net-Cash is ranked lower than
56% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. OHRP: 9.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OHRP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.57  Med: 23.39 Max: 155
Current: 9
2.57
155
Price-to-Net-Current-Asset-Value 7.88
OHRP's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OHRP: 7.88 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OHRP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.51  Med: 22.66 Max: 155
Current: 7.88
2.51
155
Price-to-Tangible-Book 7.00
OHRP's Price-to-Tangible-Book is ranked lower than
64% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. OHRP: 7.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OHRP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.49  Med: 16.27 Max: 450
Current: 7
2.49
450
Earnings Yield (Greenblatt) % -111.11
OHRP's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. OHRP: -111.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OHRP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -113.54  Med: -6.9 Max: -1
Current: -111.11
-113.54
-1

More Statistics

EPS (TTM) $ -0.87
Beta0.85
Short Percentage of Float2.67%
52-Week Range $0.56 - 4.05
Shares Outstanding (Mil)56.21
» More Articles for OHRP

Headlines

Articles On GuruFocus.com
Ohr Pharmaceutical to Present at the 2017 Marcum Microcap Conference Jun 12 2017 
Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings May 11 2017 
Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors May 11 2017 
Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11 May 09 2017 
Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD Apr 10 2017 
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants Apr 10 2017 
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants Apr 05 2017 
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants Apr 04 2017 
Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference Mar 02 2017 
CEO Invests in Ohr Pharmaceutical Jan 21 2016 

More From Other Websites
Ohr Pharmaceutical to Present at the 2017 Marcum Microcap Conference Jun 12 2017
Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors May 11 2017
Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings May 11 2017
Investor Network: Ohr Pharmaceutical Inc to Host Earnings Call May 11 2017
Ohr Pharmaceutical to Announce Fiscal Second Quarter 2017 Results on May 11 May 09 2017
Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session Apr 18 2017
Ohr Pharmaceutical Provides Update on Squalamine Study Apr 11 2017
Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD Apr 10 2017
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants Apr 10 2017
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants Apr 05 2017
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants Apr 04 2017
The Market Has Got Its Interpretation Of The OHR Pharmaceutical Inc (OHRP) Announcement Wrong Feb 15 2017
Ohr Pharmaceutical Reports 4Q Loss, Suspends Trial Feb 15 2017
Post Earnings Coverage as Ohr Pharma Reported Annual Results; Announced Closure of Public Offering Jan 05 2017
Ohr Pharmaceutical, Inc. :OHRP-US: Earnings Analysis: Q4, 2016 By the Numbers : December 27, 2016 Dec 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}